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STUDY QUESTION: Which agent for ovarian stimulation (OS) is the most cost-effective option in terms of net benefit for couples with
unexplained subfertility undergoing IUI?
SUMMARY ANSWER: In settings where a live birth is valued at e3000 or less, between e3000 and e55 000 and above e55 000,
clomiphene citrate (CC), Letrozole and gonadotrophins were the most cost-effective option in terms of net benefit, respectively.
WHAT IS KNOWN ALREADY: IUI-OS is a common first-line treatment for couples with unexplained subfertility and its increased
uptake over the past decades and related personal or reimbursed costs are pressing concerns to patients and health service providers.
However, there is no consensus on a protocol for conducting IUI-OS, with differences between countries, clinics and settings in the num-
ber of cycles, success rates, the agent for OS and the maximum number of dominant follicles in order to minimise the risk of a multiple
pregnancy. In view of this uncertainty and the association with costs, guidance is needed on the cost-effectiveness of OS agents for IUI-OS.
STUDY DESIGN, SIZE, DURATION: We developed a decision-analytic model based on a decision tree that follows couples with
unexplained subfertility from the start of IUI-OS to a protocoled maximum of six cycles, assuming couples receive four cycles on average
within one year. We chose the societal perspective, which coincides with other perspectives such as that from health care providers,
as the treatments are identical except for the stimulation agent. We based our model on parameters from a network meta-analysis of
randomised controlled trials for IUI-OS. We compared the following three agents: CC (oral medication), Letrozole (oral medication) and
gonadotrophins (subcutaneous injection).
PARTICIPANTS/MATERIALS, SETTING, METHODS: The main health outcomes were cumulative live birth and multiple
pregnancy. As the procedures are identical except for the agent used, we only considered direct medical costs of the agent during four
cycles. The main cost-effectiveness measures were the differences in costs divided by the differences in cumulative live birth (incremental
cost-effectiveness ratio, ICER) and the probability of the highest net monetary benefit in which costs for an agent were deducted from the
live births gained. The live birth rate for IUI using CC was taken from trials adhering to strict cancellation criteria included in a network
meta-analysis and extrapolated to four cycles. We took the relative risks for the live birth rate after Letrozole and gonadotrophins versus
CC from that same network meta-analysis to estimate the remaining absolute live birth rates. The uncertainty around live birth rates,
relative effectiveness and costs was assessed by probabilistic sensitivity analysis in which we drew values from distributions and repeated
this procedure 20 000 times. In addition, we changed model assumptions to assess their influence on our results.
MAIN RESULTS AND THE ROLE OF CHANCE: The agent with the lowest cumulative live birth rate over 4 IUI-OS cycles conducted
within one year was CC (29.4%), followed by Letrozole (32.0%) and gonadotrophins (34.5%). The average costs per four cycles
were e362, e434 and e1809, respectively. The ICER of Letrozole versus CC was e2809 per additional live birth, whereas the ICER of
gonadotrophins versus Letrozole was e53 831 per additional live birth. When we assume a live birth is valued at e3000 or less, CC had
the highest probability of maximally 65% to achieve the highest net benefit. Between e3000 and e55 000, Letrozole had the highest proba-
bility of maximally 62% to achieve the highest net benefit. Assuming a monetary value of e55 000 or more, gonadotrophins had the highest
probability of maximally 56% to achieve the highest net benefit.
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LIMITATIONS, REASONS FOR CAUTION: Our model focused on population level and was thus based on average costs for the
average number of four cycles conducted. We also based the model on a number of key assumptions. We changed model assumptions to
assess the influence of these assumptions on our results.
WIDER IMPLICATIONS OF THE FINDINGS: The high uncertainty surrounding our results indicate that more research is necessary
on the relative effectiveness of using CC, Letrozole or gonadotrophins for IUI-OS in terms of the cumulative live birth rate. We suggest
that in the meantime, CC or Letrozole are the preferred choice of agent.
STUDY FUNDING/COMPETING INTEREST(S): This work was supported by ZonMw Doelmatigheidsonderzoek, grant 80-85200-
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Introduction
IUI with ovarian stimulation (IUI-OS) is commonly used to treat cou-
ples with unexplained subfertility, in particular as first-line treatment
(Calhaz-Jorge et al., 2017). The ideal protocols for conducting IUI-OS
remain an ongoing debate among clinicians with differences between
countries, clinics and settings, despite efforts for global recommenda-
tions in international guidelines (Cohlen et al., 2018). A main question
that remains is: which agent can best be used for OS when conducting
IUI? Here, ‘best’ can be defined in three ways: the agent that yields
the highest cumulative live birth rate, the agent that is the safest in
terms of the lowest chance of a multiple pregnancy or the agent that
is the most cost-effective. The current international guideline specifi-
cally identified the need for more research on the cost-effectiveness of
agents used for mild stimulation in IUI protocols (Cohlen et al., 2018).
Effectiveness in terms of live birth and safety in terms of multiple
pregnancy have been addressed in a network meta-analysis (NMA)
that pooled all available data from randomised controlled trials (RCTs)
on IUI and IUI-OS (Wang et al., 2020). This NMA distinguished
between trials with and without strict cancellation criteria, defined as
cycle cancellation when exceeding three follicles of 14 millimetre.
These criteria are an effort to reduce the probability of a multiple
pregnancy. In the subgroup of trials adhering to strict cancellation
criteria there was no longer a statistically significant effect of gonado-
trophins versus CC, in contrast to the primary analysis (Wang et al.,
2020). This was mostly due to the recent SUPER trial which did not
find a large difference between these agents in terms of the cumulative
live birth rate (Danhof et al., 2018). The NMA was inconclusive as to
which agent significantly increased the chance of a multiple pregnancy.
Given the current body of evidence and contemporary recom-
mended protocol adhering to strict cancellation criteria, we are uncer-
tain which agent to use for OS, as relative effectiveness, safety and
cost-effectiveness are all unknown. A cost-effectiveness study com-
pared gonadotrophins to CC in the SUPER trial and found that gona-
dotrophins were more effective but also more costly with an
incremental cost-effectiveness ratio (ICER) of e17 044 (95% CI:
e8998–e25 090) (Danhof et al., 2019). However, this was based on a
single Dutch study in which the authors did not compare CC and
gonadotrophins to the commonly used alternative Letrozole, since
Letrozole is unregistered in the Netherlands for this indication. More
evidence is necessary on this topic to decide on sustainable, evidence-
based treatment protocols that best utilise public funds for IUI-OS
with the indication of unexplained subfertility.
The aim of the present study is to assess the cost-effectiveness of
stimulation agents for IUI-OS in couples with unexplained subfertility
by using the most up-to-date body of evidence.
Materials and methods
To answer the research question we did not use patient data, but in-
stead combined evidence from contemporary sources to develop a
statistical model commonly referred to as a decision analytic model
(Briggs et al., 2006). We chose a basic population level (average)
model based on probabilities known as a decision tree.
We reported the study according to the Consolidated Health
Economic Evaluation Reporting Standards (CHEERS) checklist. We
published the Excel sheet including all parameters that were used
(Supplementary Data File S1) and R code used to run (Supplementary
Data File S2) and analyse (Supplementary Data File S3) the model
alongside this manuscript such that other researchers can readily im-
plement the model in their own country or setting where parameters
such as costs might differ.
Population and study design
We defined subfertility as not conceiving within one year of trying.
Unexplained subfertility was defined as couples with no major causes
explaining the fertility problem, regular menstrual cycles of length be-
tween 23 and 35 days, at least one patent fallopian tube and semen
analyses with a total motile sperm count of >106 (van Eekelen et al.,
2017). Note that all literature used to develop our cost-effectiveness
model is specific to unexplained subfertile couples. As this cost-
effectiveness analysis concerns only the agents used in IUI, we chose
the health economic perspective of society. The model can be easily
modified for other perspectives or other locations. Note that the
treatments are identical in everything except for stimulation agent, and
therefore the societal perspective coincides with the perspective of
health care providers.
The three agents that we compared are all commonly used for OS
when conducting IUI in couples with unexplained subfertility:

































































































clomiphene citrate (CC), Letrozole and gonadotrophins (Wang et al.,
2020). We did not set certain dosages as we are dependent on the
body of evidence given dosages used in studies. We assumed that
strict cancellation criteria, defined as cancellation of insemination when
exceeding three follicles of 14 millimetre, were adhered to.
We chose a protocol of up to six cycles of IUI-OS to be received in
adherence to the current Dutch and international national protocol for
unexplained subfertility (NVOG, 2010; Cohlen et al., 2018; FMS,
2020). When protocol is six cycles, most couples actually receive 4
because couples can conceive in the first or second cycle, couples
drop out of IUI, couples continue to IVF before having received six
cycles, etc. (Custers et al., 2007). We therefore assumed in our model
that patients received, on average, four cycles, to be completed within
one year.
Primary data sources
Our outcome of interest is the cumulative probability of live birth as
this is the outcome that matters most to patients and quality-adjusted
life years are poorly defined for this population (Barnhart, 2014;
Eijkemans et al., 2017). As the baseline rate in the model, we chose to
use the per-cycle rate after CC in RCTs with a protocol up to four
cycles that adhered to strict cancellation criteria from the NMA
(Wang et al., 2020). This NMA only encompasses RCTs that included
unexplained subfertile patients. This is the most up-to-date live birth
rate available for the least expensive agent, given adherence to con-
temporary strict cancellation criteria protocols that minimise the
chance of a multiple pregnancy. The rate can be used to calculate the
cumulative live birth rate over any number of cycles desired, although
this represents an extrapolation. We derived the cumulative live birth
rate (CLBR) over four cycles as:
CLBR ¼ 1 1 rateð Þ4: (1)
The average rate after IUI using CC plugged into the model was
8.35%, yielding an average cumulative live birth rate over four cycles of
29.5% following the formula in (1) (Wang et al., 2020).
For the cumulative live birth rates after four cycles of Letrozole or
gonadotrophins, we used the relative risks in RCTs with a protocol up
to four cycles that adhered to strict cancellation criteria (Wang et al.,
2020). This approach has three major advantages: first, it is based on
all evidence from RCTs on IUI for unexplained subfertile couples; sec-
ond, as this evidence is from RCTs, the relative risks are marginal, i.e.
on the population level which coincides with the perspective of the de-
cision analytic model; third, these relative risks are derived from
intention-to-treat analyses that incorporate deviations from protocol
such as natural conception or changing to a different agent in a later
IUI cycle, as that would occur in clinical practice as well. The NMA
reported a relative risk of Letrozole versus CC of 1.09 (95% CI: 0.76–
1.57, only evidence in RCTs without strict cancellation criteria) and of
gonadotrophins versus CC of 1.20 (95% CI: 0.95–1.51) (Wang et al.,
2020). We thus model that all agents would lead to an average of four
cycles, assuming no difference in dropout rates between the three
agents (Danhof et al., 2018 Wang et al., 2020).
Following RCTs with a protocol up to four cycles that adhered to
strict cancellation criteria, we expected a rate of multiple pregnancy
per woman randomised of 2.5% after CC, 3% after Letrozole and
5.3% after gonadotrophins (Wang et al., 2020). A multiple pregnancy
was considered equivalent to a singleton pregnancy, i.e. a single event
in terms of ‘success’ and counting towards the live birth rate. We did
not use the relative risks for multiple pregnancy from the NMA as
these were very imprecise and not suited for network analysis.
Costs
Costs for procedures regarding IUI treatment were considered identi-
cal for all three agents. Cost data of medication for IUI-OS using CC,
Letrozole or gonadotrophins were obtained from the Dutch
Formulary on Medication (Farmacotherapeutisch Kompas, 2019).
Costs data regarding delivery of a multiple pregnancy were obtained
from an expert panel on cost-effectiveness from the Dutch consortium
for Research in Women’s Health consisting of gynaecologists, an econ-
omist and a methodologist. This group collected the total medical
costs per resource unit from two university hospitals and one general
hospital. These costs were averaged and then used to determine the
average costs of a multiple delivery.
Medication-only costs per cycle of IUI-OS were estimated at e0.90
for CC (generic), e1.00 for Letrozole (generic) and e262 for the most
commonly used gonadotrophins in the Netherlands (Gonal-F, Merck)
(Farmacotherapeutisch Kompas, 2019). Thus, after four cycles, the
expected costs were e3.60 for CC, e4.00 for Letrozole and e1048 for
gonadotrophins.
Multiple delivery cost data were from 2013, so we applied the infla-
tion factor reported by the Dutch government to update costs to
2019 (CBS, 2020). The incremental cost of delivery in case of a multi-
ple pregnancy was estimated at e14 357 and was defined as the costs
of a multiple pregnancy delivery minus the cost of a singleton delivery,
as the latter applies to all deliveries (Lukassen et al., 2004).
All details are reported in the Model Parameters Excel sheet
(Supplementary Data File S1).
Cost-effectiveness analyses
The main outcomes from the model were the cumulative live birth
rate, the average costs and the probability of multiple pregnancy. Our
model is based on a hypothetical population of couples with unex-
plained subfertility. The uncertainty around effectiveness, costs and
other parameters was assessed by probabilistic sensitivity analysis in
which we drew values from distributions and repeated this procedure
20 000 times. Thus, the basic form of our model is a Monte Carlo
simulation that executes a decision tree, replicated many times.
The structure of our decision tree model is as follows: first, for each
simulation replication, we drew values from the appropriate distribu-
tions for the relative risks, costs and the baseline rate of live birth after
CC. For each agent, we applied the relative risk to the baseline rate
and calculated the cumulative live birth rate over four cycles. We
added the costs of multiple pregnancy deliveries to the total costs.
All parameters used, their distribution and the source of evidence
are reported in Table I and are reported in more detail in the Excel
sheet. The model simulations were performed using R version 3.6.0
(R Core Team, 2017). All code necessary to run and analyse the
model is provided online at Human Reproduction.
We did not apply discounting procedures for economic analyses as
our decision analytic model covers only four cycles of IUI, assumed to
be completed within one year (Briggs et al., 2006).

































The main cost-effectiveness measures were the ICERs, the percentage
of simulation replications for each quadrant of the cost-effectiveness
plane and the probability that an agent was most likely to yield the
highest net monetary benefit.
The ICER is the increase in average cost divided by the increase in
the live birth rate for a more effective, but also more expensive agent
(Briggs et al., 2006). We opted for a step-wise approach, comparing
ICERs for increasingly more effective but also more expensive agents
(Briggs et al., 2006). We calculated the percentage of simulation repli-
cations in each quadrant of the two-dimensional cost-effectiveness
plane using the same step-wise approach.
For net (monetary) benefit, we expressed the gain for each agent
regarding live birth in terms of a monetary value. We achieved this by
multiplying the cumulative live birth rates by a monetary value between
e1 and e100 000 and deducting the total costs of that agent (Briggs
et al., 2006). The result is the monetary benefit of that agent in terms
of health gained minus the costs. For each simulation replication, we
determined which of the three agents yielded the highest net benefit
for the range of possible monetary values, then calculated the propor-
tion of simulation replications in which each agent was the best. The
results are thus interpretable as the probability that an agent yields the
highest net benefit, given that we assume live birth to be valued a cer-
tain monetary value.
Scenario analyses
In addition to the primary analysis, we changed model assumptions to
assess their influence on our results.
First, we used the relative risk for the live birth rate after gonadotro-
phins versus CC from the NMA as derived from pooled evidence on
............................................................................................................................................................................................................................
Table I Parameters, their distribution, assumptions, evaluations of assumptions and data source as used in the decision
analytic model.
























































Relative risk of Letrozole
versus CC (all trials)
Lognormal(ln(1.09)
0.1862)
0.76–1.57 Known relative effect
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Relative risk of
gonadotrophins
versus CC (trials up to




0.95–1.51 Known relative effect






Wang et al. (2020)
Relative risk of
gonadotrophins
versus CC (all trials)
Lognormal(ln(1.39)
0.1204)
1.09–1.76 Known relative effect
that relies on the base-
line rate
Scenario analysis Network meta-analysis
Wang et al. (2020)
Probability of multiple
pregnancy after CC
Beta(18.5, 721.5) 1.5–3.7% Multiple pregnancy rates










Beta(8.97, 290) 1.4–5.2% Multiple pregnancy rates










Beta(51.3, 916.7) 4.0–6.8% Multiple pregnancy rates
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Live birth rate, per cycle Beta(140, 1536) 7.1–9.7% Rate can be accurately
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Live birth rate in trials up
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..all included RCTs instead of only RCTs with protocol up to four cycles
that adhered to strict cancellation criteria. This alternative relative risk
was 1.39 (95% CI: 1.09–1.76) (also mentioned in Table I).
Second, to assess the influence of the number of average cycles that
couples received, we assumed a higher dropout rate leading to two
cycles conducted on average instead of four, changing the average
costs to e1.80 after CC, e2.00 after Letrozole and e524 after gonado-
trophins and extrapolating the live birth and multiple pregnancy rate to
2 cycles. We repeated this process but now with a protocol to con-
tinue for more than six cycles, in which we assumed the average
would be six cycles, changing the average costs to e5.40 after CC,
e6.00 after Letrozole and e1572 after gonadotrophins and extrapolat-
ing the live birth and multiple pregnancy rate to six cycles.
Third, we assumed that the baseline live birth rate was the cumula-
tive live birth rate over the total follow up in RCTs with protocol up
to four cycles that adhered to strict cancellation criteria, which was
24.6% (Wang et al., 2020).
Fourth, we chose parameters based on a previous analysis of the in-
dividual participant data (IPD) from authors of trials that were included
in the NMA and whom provided their data (Wang et al., 2020). This
changed the cumulative live birth rate after CC to 29.8%, the relative
risk of Letrozole versus CC to 0.80 (95% CI: 0.59–1.10) and the rela-
tive risk of gonadotrophins versus CC to 1.28 (95% CI: 1.04–1.66).
Results
The main results are displayed in Table II. The agent with the lowest
cumulative live birth rate was CC (29.4%), then Letrozole (32.0%) and
gonadotrophins with the highest (34.5%). The average costs were
e362, e434 and e1809, respectively. This meant that Letrozole was
more effective but also more costly than CC and gonadotrophins were
more effective and more costly than both CC and Letrozole. The ICER
for Letrozole was e2809 compared to CC. The ICER for gonadotro-
phins was e53 831 compared to Letrozole. The range of ICER values
between the lowest 2.5% and highest 97.5% of simulation replications
was extremely broad, reflecting the very high uncertainties in the rela-
tive risk estimates in addition to uncertainty in the average costs.
The percentages of simulation replications for each quadrant of the
cost-effectiveness plane are presented in Table III. Despite the point
estimates showing that Letrozole was more effective but also more
costly than CC, this only occurred in 44.0% of replications (north-east
quadrant). In 23.3% of replications, Letrozole dominated CC, i.e. being
more effective and less costly. In 21.6% of replications, Letrozole was
inferior to CC, being less effective and more costly. Similarly, despite
the point estimates showing that gonadotrophins were more effective
but also more costly than Letrozole, this only occurred in 67.4% of
replications (north-east quadrant). In the remaining 32.6%, gonadotro-
phins were inferior to Letrozole. These results reaffirm the finding in
ICERs that the uncertainty around parameters was very high.
The net benefit curves for a range of monetary value per live birth
are shown in Fig. 1.
The curve showed that when we assume a live birth to value be-
tween e1 and e3000, CC had the highest probability of maximally
65% to achieve the highest net benefit. Between e3000 and e55 000,
Letrozole had the highest probability of maximally 62% to achieve the
highest net benefit. Assuming a monetary value of e55 000 or more,
gonadotrophins had the highest probability of maximally 56% to
achieve the highest net benefit. The curve in Fig. 2 is identical to Fig. 1
but shows only the best performing agent over the range of monetary
values. The probabilities to yield the highest benefit never exceeded
65%, reflecting the high uncertainty in the parameters and indicating a
low certainty that the agents are truly better at these different mone-
tary values.
In short, when assuming a live birth to be ‘valued’ a low, intermedi-
ate or high amount of money, the most cost-effective agent was CC,
Letrozole or gonadotrophins, respectively. Unfortunately, the uncer-
tainty surrounding results was high, not allowing for strict cut-offs for
these values.
Scenario analyses
The ICER for gonadotrophins versus Letrozole was lower in the sce-
nario analysis in which we used the higher relative risk for gonadotro-
phins based on all included trials in the NMA, at e19 500
(Supplementary Table SI). However, the 95% CI limits remained ex-
tremely broad. From a monetary value of approximately e20 000 on-
wards, gonadotrophins now were the most likely to yield the highest
net benefit, with a maximum probability of approximately 81%
(Supplementary Fig. S1).
The ICER for gonadotrophins versus Letrozole with 2 cycles instead
of 4 was slightly lower than the primary analysis at e45 000
............................................................................................................................................................................................................................
Table II Main outcomes from the cost-effectiveness analysis (all agents).
Agent
Cumulative probability









Clomiphene citrate 29.4 362 2.5 0 (reference)
Letrozole 32.0 434 3.0 2809 (95% CI:
–46 462 to 41 136)
Gonadotrophins 34.5 1809 5.3 53 831 (95% CI:
–294 542 to 345 764)
All costs in eEUR.
*Step-wise approach first comparing Letrozole to clomiphene citrate and second gonadotrophins to Letrozole.








































..(Supplementary Table SII). The ICER for six cycles instead of four was
slightly higher than the primary analysis at e67 000 (Supplementary
Table SIII). However, the 95% CI limits remained extremely broad.
Both net benefit curves were similar to the primary analysis,
with slightly shifted crossover points but identical patterns in terms of
the probability that one agent yields the highest net benefit
(Supplementary Fig. S2a and b).
Results for both the ICERs and the net benefit curves in the sce-
nario analysis in which we used the cumulative live birth rate from tri-
als that protocoled up to four cycles with adherence to strict
cancellation criteria were very similar to the primary analysis
(Supplementary Table SIV and Fig. S3).
CC dominated Letrozole in the scenario analysis when using param-
eters based on the IPD, as CC was more effective and less expensive.
Gonadotrophins were significantly more effective than CC but also sig-
nificantly more expensive, with an ICER of approximately e20 500
(Supplementary Table SV and Fig. S4). The net benefit curve now
shows Letrozole as the worst option at any monetary value. If a live
birth is assumed to be valued e15 000 or less, CC was the most likely
to yield the highest net benefit, with a probability of 80% or higher. If
a live birth is assumed to be valued e33 000 or more, gonadotrophins
were the most likely to yield the highest net benefit, with a probability
of 80% or higher. Between e15 000 and e33 000, it was uncertain
which agent yielded the highest net benefit.
Discussion
We found that if stakeholders or society as a whole consider a live
birth to be valued a relatively low monetary value (e3000 or less), the
least expensive but most cost-effective agent in an IUI-OS protocol in
terms of net benefit was CC. If a live birth is considered to be valued
between e3000 and e55 000, Letrozole was the most cost-effective
agent. If a live birth is considered to be valued e55 000 or more, gona-
dotrophins were the most cost-effective agent. The probability that
one agent was the most cost-effective never exceeded 65%, indicating
the high uncertainty in model parameters and results. When we used
the parameters from the IPDMA, which we consider as a selection of
studies that were generally of higher quality, the relative effects were
more precise and Letrozole was now found less effective than CC and
............................................................................................................................................................................................................................







North-west (less effective and
more expensive i.e. inferior)
South-east (more effective and
less expensive i.e. dominant)
Letrozole versus Clomiphene citrate 44.0% 11.1% 21.6% 23.3%
Gonadotrophins versus Letrozole 67.4% 0% 32.6% 0%
Figure 1. Net benefit curves for all agents.

























































.gonadotrophins significantly more effective than CC. The net benefit
curve showed CC as the best option below a monetary value of e15
000 per live birth and gonadotrophins as the best option above a
monetary value of e33 000.
Strengths of this study include the use of evidence from a contempo-
rary NMA that combined all evidence from RCTs conducted in IUI-OS
for unexplained subfertility for all three relevant, often-used agents. In
addition, uncertainty was incorporated by alternative assumptions in our
scenario analyses as well as using distributions in a probabilistic sensitivity
analysis in which the model simulation was repeated 20 000 times.
As mentioned, there was a very high uncertainty surrounding esti-
mates for the decision analytic model shown in both the 95% CI limits
for the ICER and, more informatively, in the net benefit curves. The
uncertainty was highest surrounding the relative effectiveness of gona-
dotrophins and Letrozole as compared to CC. In the subgroup analy-
sis for trials that protocoled up to four cycles of IUI and adhered to
strict cancellation criteria, there were no direct comparisons between
Letrozole and CC and thus we had to use the relative risk from the
remaining trials.
Our model, although based on contemporary evidence, was not
free of assumptions and was based on average costs for an average
number of cycles, assumed to be completed within 1 year. This reflects
the societal perspective on population level, i.e. average costs.
Most of our scenario analyses showed similar results as in the pri-
mary analysis except when we used the relative risk parameters from
the IPD. This was mainly due to the inclusion of trials that did not ad-
here to strict cancellation criteria: Letrozole then led to fewer live
births and the relative effect of gonadotrophins on live birth was fur-
ther away from 1 and statistically significant, both compared to CC.
There remained great uncertainty surrounding the ICER and in the net
benefit curve, showing that between a monetary value of e15 000 and
e33 000 per live birth, it remained unknown which option was likely
to yield the highest net benefit.
There is no consensus on what society deems “cost-effective” or
“worth investing” regarding live birth, which complicates decision mak-
ing. Especially in the framework of net benefit, in which a live birth on
itself is declared to be of certain monetary value rather than the in-
vestment required to gain one additional live birth for option A com-
pared to option B, this can be a sensitive topic. Preferences vary for
stakeholders and perspective and, in particular, depend on country
and health care system. The net benefit curve allows readers to inter-
pret from their own perspective.
Our results beg once more for a re-evaluation of the recommended
protocols for IUI-OS. In particular, our results call for more research
on the relative effectiveness of both Letrozole and gonadotrophins
versus CC: Letrozole as the least data was available and its effective-
ness remains very uncertain and gonadotrophins as they are 291 times
more expensive as a dosage per cycle as compared to CC at approxi-
mately e262 versus e0.90. Our study shows that this steep difference
in price is unwarranted in terms of the probability of live birth.
Couples who pay for their own treatment and medication can reduce
spending considerably without evidence of decreasing their probability
of live birth. Insurance companies and governments can cut costs with-
out evidence of harming patients.
We suggest that with the current body of evidence, CC or
Letrozole are the preferred choice of agent.
The results of our study can be used in discussions between clini-
cians, couples and policy makers to decide on a sustainable treatment
protocol on IUI-OS for couples with unexplained subfertility. Our
model used contemporary evidence and all necessary code is provided
such that it is easy to apply in other countries where, for instance,
costs might differ.
Figure 2. The cost-effective frontier for the net benefit curves.


































































































The high uncertainty surrounding our results indicate that more research is
necessary on the relative effectiveness of using CC, Letrozole or gonado-
trophins for IUI-OS in terms of the cumulative live birth rate. We suggest
that in the meantime, CC or Letrozole are the preferred choice of agent.
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